Eiger Bio to Participate in September 2020 Investor Conferences

On September 1, 2020 Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, reported that management will participate in four investor conferences in September (Press release, Eiger Biopharmaceuticals, SEP 1, 2020, View Source [SID1234564259]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 15th Annual BioPharma Conference. Eiger will participate in two panels:
"COVID-19 Therapeutics" on Wednesday, September 9, 9:50-10:20 AM ET
"Challenges and Opportunities in Rare Disease Drug Development" on Wednesday, September 9, 4:15-4:45 PM ET

Baird Global Healthcare Conference 2020. Eiger will present a corporate update on Wednesday, September 9, 12:50-1:20 PM ET.

H.C. Wainwright 22nd Annual Global Investment Conference from September 14- September 16.

Cantor Global Virtual Healthcare Conference 2020. Eiger will present a corporate update on Thursday, September 17, 2:00-2:30 PM ET.
Eiger will host one-on-one meetings at all conferences. Live webcasts of the Citi panels and Baird and Cantor presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the live event.

Nevro to Present at Upcoming Conferences

On September 1, 2020 Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, reported that D. Keith Grossman, Nevro’s Chairman, CEO and President, will present at the following conferences (Press release, Nevro, SEP 1, 2020, View Source [SID1234564258]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 2020 Virtual Healthcare Conference
Wednesday, Sept. 9, 2020 at 4:00 pm ET

Morgan Stanley 18th Annual Global Healthcare Conference
Monday, Sept. 14, 2020 at 3:00 pm ET

A live webcast of these events will be available on the Investors section of Nevro’s website at www.nevro.com. A webcast replay will be available approximately one hour after each live webcast ends and will be accessible for approximately 14 days.

Theravance Biopharma to Present at Upcoming Investor Conferences

On September 1, 2020 Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, reported that it will webcast Management presentations as follows (Press release, Theravance, SEP 1, 2020, View Source [SID1234564257]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 18th Annual Global Healthcare Conference 2020 on Monday, September 14 at 1:30 p.m. ET (10:30 a.m. PT/5:30 p.m. GMT)
H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 9:30 a.m. ET (6:30 a.m. PT/1:30 p.m. GMT)
Webcasts of the presentations may be accessed by visiting the "Investors" section of Theravance Biopharma’s website at www.theravance.com under the "Presentations and Events" tab. Replays of the webcasts will be archived on the Company’s website for at least 30 days.

Nordic Nanovector to Present at Upcoming Pareto Securities 11 th Healthcare Conference

On September 1, 2020 Nordic Nanovector ASA (OSE: NANO) reported that its management team will present a corporate overview and host one-on-one meetings with investors at the Pareto Securities 11th Healthcare Conference, taking place 2nd-3rd September 2020 (Press release, Nordic Nanovector, SEP 1, 2020, View Source [SID1234564255]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will take place at 15:00hrs CEST on Thursday, 3rd September.

The company presentation will be available on Nordic Nanovector’s Investors and Media page at the same time.

Evogene Announces $10 Million Equity Led Investment by ARK Investment Management, LLC

On September 1, 2020 Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, reported that it has entered into a definitive agreement with ARK Investment Management, LLC (ARK Invest) and Alpha Capital Anstalt in connection with a registered direct offering of ordinary shares at a price per share of $1.70, for an aggregate cash consideration of $10 million (Press release, Evogene, SEP 1, 2020, View Source [SID1234564254]). Of the aggregate investment amount, ARK Invest, a leading technology investment firm, specializing in thematic investing in disruptive innovation, will invest $7 million and Alpha Capital Anstalt will invest $3 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evogene intends to use the net proceeds from the offering to further develop its and its subsidiaries’ product pipelines, to further enhance and expand its computational predictive biology platform, and for working capital and general corporate purposes.

The offering is expected to close on or before September 3, 2020, subject to customary closing conditions.

The shares of common stock offered in the registered direct offering described above are being offered by Evogene pursuant to its shelf registration statement on Form F-3 (File No.333-240249) previously filed and declared effective by the Securities and Exchange Commission (the "SEC") on August 10, 2020. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website.

This press release is for informational purposes only and should not be construed as investment advice and does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.